放射性同位素治療腫瘤骨轉移性疼痛的系統評價_《中國循證醫學雜志》

作者：

王新玲 ¹ , 廖燚 ² , 吳泰相 ³

1. 新疆克拉瑪依市中心醫院核醫學科,克拉瑪依,8340002. 新疆克拉瑪依市中心醫院骨科,克拉瑪依,8340003. 四川大學華西醫院中國循證醫學中心/臨床流行病學資源與培訓中心,成都,610041;

關鍵詞：

腫瘤轉移骨轉移性疼痛放射性同位素系統評價

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　對放射性同位素治療腫瘤骨轉移疼痛的效果及其副作用進行評價.
方法　計算機檢索MEDLINE(1966～2005.4)、EMBASE (1966～2005.4)、Cochrane圖書館(2005年第1期)及中國生物醫學文獻數據庫(1979～2005.4),收集所有相關隨機對照試驗,對其質量進行評價,而用RevMan 4.2版軟件進行Meta分析.
結果　共納入4個隨機對照試驗.Meta分析結果顯示,使用150MBq放射性同位素時,短期內(2個月)控制腫瘤骨轉移性疼痛的效果不明顯[RR1.13, 95%CI(0.34,3.76)],而使用10.8 mCi劑量時,中期(6個月)完全緩解率的效果顯著[RR 1.90,95%CI(1.23,2.92)];沒有長期(≥1年)效果的報道.與放射性同位素使用有關的副作用特別是白細胞減少及血小板減少的發生率均增加[分別為RR 8.28,95%CI(2.24,30.67)和RR 3.70, 95%CI(1.59,9.04)].放射性同位素對由于腫瘤骨轉移所致脊髓壓迫的發生無影響.沒有研究報道有關高鈣血癥、骨折等骨轉移性并發癥的發生情況.
結論　使用一定劑量的放射性同位素在短中期內能緩解腫瘤骨轉移性疼痛,但白細胞減少與血小板減少的發生率增加.

引用本文： 王新玲,廖燚,吳泰相. 放射性同位素治療腫瘤骨轉移性疼痛的系統評價. 中國循證醫學雜志, 2005, 05(6): 455-460. doi: 復制

1.	Portenoy RK. Cancer Pain. Epidemiology and pain syndromes[J]. Cancer, 1989; 63(11 Suppl): 2298-2307.
2.	Nelson OS, Munro AJ, Tannock IF. Bone metastatic: pathophysiology and management policy[J]. J Clin Oncol, 1991; 9(3):509-524.
3.	Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications[J]. J Bone Joint Surg Am, 2002; 84-A(1):49-57.
4.	Mertens WC, Filipczack LA, Ben-Josef Edgar, Davis LP, Portes AT. Systemic bone-seeking Radionuclides for palliation of painful osseous metastases: Current Concepts[J]. CA Cancer J Clin, 1998; 48(6):361-374.
5.	Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’Handbook 4.2.1[updated December 2003]. Section 6. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
6.	Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone[J]. European Journal of Cancer, 1991; 27(8):954-958.
7.	Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer[J]. INT-J-RADIAT-ONCOL-BIOL-PHYS, 1993; 25(5): 805-813.
8.	Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial[J]. Journal of Clinical Oncology, 1998; 16(4):1574-1581.
9.	Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma[J]. European Journal of Nuclear Medicine, 1988; 14(7-8):349-351.
10.	Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM, Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer[J]. Radiotherapy & Oncology, 1994; 31(1): 33-40.
11.	Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Vergleich von Rhenium-188-HEDP, Rhenium-186-HEDP und Strontium-89 fur die palliative Schmerztherapie von Skelettmetastasen[J]. Nuklearmedizin, 2000; 39(6): 146-151.
12.	Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. European Journal of Nuclear Medicine, 1999; 26(1):2-7.
13.	Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. European Journal of Nuclear Medicine, 1999; 26(1):2-7.

1. Portenoy RK. Cancer Pain. Epidemiology and pain syndromes[J]. Cancer, 1989; 63(11 Suppl): 2298-2307.
2. Nelson OS, Munro AJ, Tannock IF. Bone metastatic: pathophysiology and management policy[J]. J Clin Oncol, 1991; 9(3):509-524.
3. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications[J]. J Bone Joint Surg Am, 2002; 84-A(1):49-57.
4. Mertens WC, Filipczack LA, Ben-Josef Edgar, Davis LP, Portes AT. Systemic bone-seeking Radionuclides for palliation of painful osseous metastases: Current Concepts[J]. CA Cancer J Clin, 1998; 48(6):361-374.
5. Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’Handbook 4.2.1[updated December 2003]. Section 6. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
6. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone[J]. European Journal of Cancer, 1991; 27(8):954-958.
7. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer[J]. INT-J-RADIAT-ONCOL-BIOL-PHYS, 1993; 25(5): 805-813.
8. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial[J]. Journal of Clinical Oncology, 1998; 16(4):1574-1581.
9. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma[J]. European Journal of Nuclear Medicine, 1988; 14(7-8):349-351.
10. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM, Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer[J]. Radiotherapy & Oncology, 1994; 31(1): 33-40.
11. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Vergleich von Rhenium-188-HEDP, Rhenium-186-HEDP und Strontium-89 fur die palliative Schmerztherapie von Skelettmetastasen[J]. Nuklearmedizin, 2000; 39(6): 146-151.
12. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. European Journal of Nuclear Medicine, 1999; 26(1):2-7.
13. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J]. European Journal of Nuclear Medicine, 1999; 26(1):2-7.

《中國循證醫學雜志》

放射性同位素治療腫瘤骨轉移性疼痛的系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

放射性同位素治療腫瘤骨轉移性疼痛的系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料